| Overview |
| bs-8331R |
| CPXCR1 Polyclonal Antibody |
| WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Horse |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CPXCR1 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 53336 |
| Cytoplasm, Nucleus, Secreted, Extracellular matrix |
| Cancer/testis antigen 77; CPX chromosome region, candidate 1; CPX candidate region 1 protein; CPX chromosomal region candidate gene 1 protein; CPX chromosomal region candidate gene 1 protein homolog; CPX chromosome region, candidate 1; CT77; Gm1143; CPXCR_HUMAN. |
| CPXCR1 is widely expressed in fetal tissues, including the tongue, mandible and palate with an unknown function. Cleft palate most commonly occurs as a sporadic multifactorial disorder with a clear but difficult to define genetic component. As a semi-dominant disorder, X-linked cleft palate (CPX) provides a useful model to investigate a congenital defect that is little influenced by non-genetic factors. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |